Brand Name

Dexilant

Generic Name
Dexlansoprazole
View Brand Information
FDA approval date: April 12, 2010
Classification: Proton Pump Inhibitor
Form: Capsule

What is Dexilant (Dexlansoprazole)?

Dexlansoprazole delayed-release capsules are proton pump inhibitor indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis .

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Evaluating the Effectiveness of Anti- Ulcerants (Dexlansoprazole, Lansoprazole, and Vonoprazan) With Levofloxacin-based Triple Therapy for Helicobacter Pylori Eradication - A Three-arm Randomized Controlled Trial
Evaluating the Effectiveness of Anti- Ulcerants (Dexlansoprazole, Lansoprazole, and Vonoprazan) With Levofloxacin-based Triple Therapy for Helicobacter Pylori Eradication - A Three-arm Randomized Controlled Trial
Enrollment Status: Recruiting
Publish Date: January 15, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: This study, titled CURE-H. Pylori, is a three-arm, parallel-group, open-label, randomized controlled trial designed to evaluate the effectiveness of Dexlansoprazole, Lansoprazole, and Vonoprazan in combination with Levofloxacin and Amoxicillin for Helicobacter pylori eradication. H. pylori infection is a significant health issue worldwide, with an estimated prevalence of 44% globally and around 60...

A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
Who is this study for: Pediatric patients aged 2 to 11 years with symptomatic nonerosive gastroesophageal reflux disease
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drug: Dexlansoprazole
Study Phase: Phase 2

Summary: Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth ...

View All Clinical Trials

Related Latest Advances

Proton Pump Inhibitors and the Risk of Dementia.
Proton Pump Inhibitors and the Risk of Dementia.
Journal: The Journal of clinical psychiatry
Published: April 15, 2026
Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation.
Intranasal Nanoemulsion-based In-Situ Gel Containing Dexlansoprazole: Formulation Development, In-Vitro and Ex-Vivo Evaluation.
Journal: Drug development and industrial pharmacy
Published: April 11, 2026
A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias.
A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias.
Journal: Journal of clinical medicine
Published: November 09, 2025
View All Latest Advances